Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. reports news on its global medtech business, which supplies hospitals, physician offices and other care settings with connected solutions, medical devices and advanced injectable technologies. Company updates commonly cover results from continuing operations following the Kidney Care divestiture, portfolio activity in infusion therapies and platforms, surgical tables, smart stretchers, patient-support systems, monitoring tools, and hemostatic and sealing agents.
Baxter announcements also address product introductions such as the IV Verify Line Labeling System, conference showcases for Global Surgical Solutions, Advanced Surgery and Patient Support Systems, annual-meeting matters, executive finance leadership, and foundation partnerships tied to healthcare settings.
Baxter International Inc. (NYSE:BAX) has declared a quarterly cash dividend of $0.29 per share of common stock, with an indicated annual dividend rate of $1.16 per share. The dividend will be payable on July 1, 2024, to stockholders of record as of May 31, 2024.
Baxter International Inc. reported first-quarter 2024 results with sales of $3.59 billion, up 2% on a reported basis and 3% on a constant currency basis, surpassing guidance. U.S. GAAP EPS was $0.07, adjusted EPS was $0.65. Full-year sales growth outlook is 2% (reported) and 2-3% (constant currency). Recent FDA clearance of Novum IQ large volume infusion pump and Dose IQ Safety Software. Baxter is focused on operational execution, innovation, and value creation for stakeholders.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.